NPPB and myocardial infarction: The recently published “Empagliflozin in acute myocardial infarction” (EMMY) trial was the first clinical trial highlighting a significant reduction in N-terminal pro-hormone of brain natriuretic peptide (NTproBNP) levels as well as structural (left ventricular end-diastolic and end-systolic diameter [LVEDD, LVESD]) and functional cardiac parameters (LVEF, E/eʹ) in patients with and without diabetes suffering from acute myocardial infraction (AMI), receiving Empagliflozin in addition to guideline recommended post-MI treatment11.